Tempus AI (NASDAQ:TEM) Upgraded to “Buy” at TD Cowen

TD Cowen upgraded shares of Tempus AI (NASDAQ:TEM) from a hold rating to a buy rating in a research note published on Monday morning, MarketBeat.com reports. TD Cowen currently has $65.00 target price on the stock.

Other equities analysts have also issued research reports about the stock. JPMorgan Chase & Co. cut their price objective on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Guggenheim cut their price objective on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 price objective on shares of Tempus AI in a research report on Wednesday, March 11th. Finally, Jefferies Financial Group assumed coverage on shares of Tempus AI in a research report on Monday. They set an “underperform” rating and a $35.00 price objective on the stock. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Tempus AI presently has an average rating of “Moderate Buy” and a consensus target price of $71.36.

Tempus AI Price Performance

Shares of TEM opened at $45.98 on Monday. The firm has a market cap of $8.22 billion, a PE ratio of -32.61 and a beta of 4.90. The firm’s 50 day moving average price is $50.85 and its 200 day moving average price is $66.55. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13. Tempus AI has a twelve month low of $39.01 and a twelve month high of $104.32.

Insider Buying and Selling

In other news, CEO Eric P. Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $65.56, for a total value of $10,899,350.00. Following the transaction, the chief executive officer owned 8,941,533 shares of the company’s stock, valued at $586,206,903.48. This trade represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Ryan Fukushima sold 9,592 shares of Tempus AI stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $566,407.60. Following the completion of the transaction, the chief executive officer directly owned 694,354 shares in the company, valued at approximately $41,001,603.70. This represents a 1.36% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 563,841 shares of company stock valued at $32,258,311. 26.27% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. grew its stake in shares of Tempus AI by 1.5% in the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after acquiring an additional 162 shares during the last quarter. Global Retirement Partners LLC grew its stake in shares of Tempus AI by 29.5% in the third quarter. Global Retirement Partners LLC now owns 733 shares of the company’s stock worth $59,000 after acquiring an additional 167 shares during the last quarter. US Bancorp DE grew its stake in shares of Tempus AI by 6.6% in the third quarter. US Bancorp DE now owns 2,848 shares of the company’s stock worth $230,000 after acquiring an additional 176 shares during the last quarter. Legacy Bridge LLC grew its stake in shares of Tempus AI by 1.6% in the fourth quarter. Legacy Bridge LLC now owns 12,418 shares of the company’s stock worth $733,000 after acquiring an additional 193 shares during the last quarter. Finally, Truist Financial Corp grew its stake in shares of Tempus AI by 5.8% in the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock worth $209,000 after acquiring an additional 194 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.